← Insider buys
LXRX

Lexicon Pharmaceuticals, Inc. · Healthcare

Invus Public Equities, L.P. bought $5.0M of Lexicon Pharmaceuticals, Inc.

Director and 10% owner

Bought$5,002,667
$12.01Price
416,481Shares
+1%Stake

What LXRX did for a copier

Prices for LXRX after this filing aren't in yet.

Invus Public Equities, L.P.'s record

5 other buys with 3 months of prices since 2017: on average −13.9% against the S&P 500, and 2 of 5 beat it.

We're building an app that can copy buys like this into your own brokerage. Join the waitlist

Traded Thu, May 31. Filed Mon, Jun 4, 1:31 PM ET, during the session. Not investment advice.